Thus, blocking cathelicidin could be a therapeutic strategy to reduce inflammation and improve insulin sensitivity in patients with obesity and MetS, paving the way for new treatments targeting AT inflammation (Table 1). The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.